Targets › RDH12
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2032.
Retinoids dehydrogenase/reductase with a clear preference for NADP. Displays high activity towards 9-cis, 11-cis and all-trans-retinal. Shows very weak activity towards 13-cis-retinol. (UniProt, Q96NR8)
Open in Phaseline: the race on RDH12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Opus Genetics | OPGx-RDH12 Gene therapy delivering functional RDH12 gene to retinal cells | RDH12 | Phase 1 | Leber Congenital Amaurosis | Dec 2032 |
Leber Congenital Amaurosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.